Biohaven Q3 2025 Earnings Report

Biohaven EPS Results

• Actual EPS: -$1.64
• Consensus EPS: -$1.91
• Beat/Miss: Beat by +$0.27
• One Year Ago EPS: N/A

Biohaven Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.34 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Biohaven Announcement Details

• Quarter: Q3 2025
• Date: 11/10/2025
• Time: Before Market Opens
• Conference Call Date: Monday, November 10, 2025
• Conference Call Time: 7:00AM ET

Biohaven (NYSE:BHVN) (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine. Its lead product, rimegepant—commercially marketed under the name NURTEC® ODT—has been approved for both acute migraine relief and migraine prevention in adults. Biohaven’s pipeline also includes atogepant, a once-daily oral CGRP receptor antagonist in late-stage development for migraine prevention, as well as earlier-stage candidates targeting N-methyl-D-aspartate (NMDA) receptors for chronic pain and other neurological disorders.

In addition to its internal programs, Biohaven has established global licensing agreements and co-development partnerships to expand the reach of its migraine therapies in key markets such as Europe, Canada and Asia. The company leverages a hybrid model of in-house development and external collaborations to accelerate clinical progress and broaden patient access.

Under the leadership of Founder and Chief Executive Officer Dr. Vlad Coric, Biohaven has built a multidisciplinary management team with deep experience in neuroscience drug development and commercial operations. Together, they aim to advance the company’s portfolio through late-stage clinical trials and regulatory submissions, with the goal of delivering novel treatments that improve patient outcomes in neurological and central nervous system disorders.